Tiffany Nelson
Family · Sedalia, MONPI 1225565948
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $137,889 of the $163,541 with a category attached, or 84.3%. Teva Pharmaceuticals USA, Inc. accounts for 99.0% of it on its own, with 6 other manufacturers making up the rest. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $720.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$162K
- Neuronetics, Inc.$1K
- AbbVie$180
- Neurocrine Biosciences, Inc.$116
- E.r. Squibb & Sons, L.L.C.$82
- Avanir Pharmaceuticals, Inc.$49
- plus $17 from 1 others
What the payments were for
- Consulting fees$8401%
- Speaking & faculty fees$137,88984%
- Travel & lodging$18,99212%
- Food & beverage$5,7113%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 209 | $161,882 |
| Neuronetics, Inc. | 2 | $1,216 |
| AbbVie | 3 | $180 |
| Neurocrine Biosciences, Inc. | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Avanir Pharmaceuticals, Inc. | 2 | $49 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$92,832
- UZEDY$66,892
- NEUROSTAR TMS THERAPY SYSTEM$1,216
How this compares
$163,541 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 371 | $1,313,820 |
| UzedyRisperidone | 235 | $811,900 |
| IngrezzaValbenazine Tosylate | 83 | $310,959 |
| AustedoDeutetrabenazine | 78 | $302,576 |
| Abilify MaintenaAripiprazole | 96 | $287,296 |
| Risperdal ConstaRisperidone Microspheres | 105 | $150,175 |
| Chlorpromazine Hcl | 883 | $112,368 |
| AristadaAripiprazole Lauroxil | 35 | $110,025 |
| RexultiBrexpiprazole | 96 | $70,392 |
| Clozapine | 804 | $46,750 |
| Divalproex Sodium | 653 | $38,330 |
| Olanzapine | 730 | $29,173 |
| Risperidone ErRisperidone Microspheres | 15 | $24,356 |
| Aripiprazole | 251 | $20,975 |
| XifaxanRifaximin | 11 | $18,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $17 | $1,463,995476 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo | $161,882 | $1,114,476313 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $116 | $310,95983 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Sedalia
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
- Jordan PerezSaint Louis$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.